Research groups
Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Programming and Data Management Director
Automation and Semantic Interoperability in Clinical Trials
Yama F Mujadidi is the Programming and Data Management Director at the Oxford Vaccine Group. In this role, he provides strategic leadership across the Group’s global portfolio of clinical research, with responsibility for data governance, IT infrastructure, programming, and data management systems.
With more than a decade of experience in clinical trials data management and software engineering, he has led the development and validation of electronic data capture systems (MHRA/GxP/FDA compliant), large-scale database infrastructures, and large language models. His expertise spans information governance, clinical trial regulations, and project management, underpinned by a proven ability to lead multidisciplinary technical teams.
Since joining the Oxford Vaccine Group in 2013, Yama has contributed to major international vaccine trials, trained and mentored research teams in the UK and globally, and co-authored numerous publications in high-impact journals. He has also taken a leading role in advancing novel approaches to clinical trial database design and semantic interoperability.
His achievements have been recognised through several awards, including the Fazlur Rahman Khan Award for Excellence in Engineering and Science (2013), the Association for Clinical Data Management’s Individual Excellence Award (2024), and recognition as Best Muslim in STEM by British Muslim (2024).
Beyond Oxford, Yama is an entrepreneur and founder of organisations advancing educational and technological innovation for global health. He is currently pursuing a DPhil at the University of Oxford on automation and semantic interoperability in clinical trials. Alongside his academic and professional commitments, he serves as a delegate with UN Women UK, advocating for the rights of women and children.
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Li G. et al, (2025), Vaccine, 62
-
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
Janani L. et al, (2025), J Infect
-
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
-
Precision Data Management: Using REDCap and Large Language Models to Optimise Clinical Trial Efficiency
Mujadidi YF. et al, (2025)
-
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Feng S. et al, (2025), J Infect, 90
-
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa
Chanda C. et al, (2025), The Lancet Microbe
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Conlin K. et al, (2024), Vaccine, 45
-
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
Qadri F. et al, (2024), Lancet, 404, 1419 - 1429
-
Modelling Salmonella Typhi in high-density urban Blantyre neighbourhood, Malawi, using point pattern methods.
Khaki JJ. et al, (2024), Sci Rep, 14
-
Pathogen diversity and antimicrobial resistance transmission of Salmonella enterica serovars Typhi and Paratyphi A in Bangladesh, Nepal, and Malawi: a genomic epidemiological study.
Dyson ZA. et al, (2024), Lancet Microbe
-
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Jackson S. et al, (2024), Lancet Microbe, 5, 655 - 668
-
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025
-
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Hill M. et al, (2023), BMJ Open, 13
-
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E. et al, (2023), J Infect, 87, 230 - 241
-
Direct inference and control of genetic population structure from RNA sequencing data.
Fachrul M. et al, (2023), Commun Biol, 6
-
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Kelly S. et al, (2023), Trials, 24
-
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Liu X. et al, (2023), J Infect, 87, 18 - 26
-
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
-
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X. et al, (2023), J Infect, 86, 540 - 541
-
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Khanam F. et al, (2023), Vaccine
-
The rapid emergence ofSalmonellaTyphi with decreased ciprofloxacin susceptibility following an increase in ciprofloxacin prescriptions in Blantyre, Malawi
Ashton PM. et al, (2023)
-
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
-
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
-
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S. et al, (2022), Lancet Glob Health, 10, e1494 - e1504
-
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Bendor-Samuel OM. et al, (2022), Arch Dis Child
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
-
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS. et al, (2022), Lancet Infect Dis
-
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Ogbe A. et al, (2022), JCI Insight, 7
-
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial.
Liu X. et al, (2022), J Infect